Bicara Therapeutics Common Stock Market Outlook
| BCAX Stock | 13.99 0.81 5.47% |
Slightly above 65% of Bicara Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Bicara Therapeutics Common suggests that many traders are alarmed. Bicara Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Bicara Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 35
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Bicara Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Bicara Therapeutics Common.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Bicara Therapeutics Common is 'Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Bicara Therapeutics Common given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Bicara Therapeutics Common, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Bicara Therapeutics Advice
The Bicara recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Bicara Therapeutics Common. Macroaxis does not own or have any residual interests in Bicara Therapeutics Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bicara Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Bicara Therapeutics Common has a Mean Deviation of 2.85, Semi Deviation of 3.09, Standard Deviation of 3.66, Variance of 13.4, Downside Variance of 9.93 and Semi Variance of 9.57Our trade advice tool can cross-verify current analyst consensus on Bicara Therapeutics and to analyze the company potential to grow in the current economic cycle. To make sure Bicara Therapeutics is not overpriced, please confirm all Bicara Therapeutics fundamentals, including its total debt, and the relationship between the shares owned by institutions and target price . Given that Bicara Therapeutics has a shares owned by institutions of 92.48 %, we suggest you to validate Bicara Therapeutics Common market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Bicara Therapeutics Trading Alerts and Improvement Suggestions
| Bicara Therapeutics had very high historical volatility over the last 90 days | |
| Bicara Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bicara Therapeutics generates negative cash flow from operations | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635 |
Bicara Therapeutics Returns Distribution Density
The distribution of Bicara Therapeutics' historical returns is an attempt to chart the uncertainty of Bicara Therapeutics' future price movements. The chart of the probability distribution of Bicara Therapeutics daily returns describes the distribution of returns around its average expected value. We use Bicara Therapeutics Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bicara Therapeutics returns is essential to provide solid investment analysis for Bicara Therapeutics.
| Mean Return | 0.09 | Value At Risk | -4.85 | Potential Upside | 6.05 | Standard Deviation | 3.66 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bicara Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bicara Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bicara Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bicara Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bicara stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.03 | |
β | Beta against Dow Jones | 0.50 | |
σ | Overall volatility | 3.64 | |
Ir | Information ratio | -0.0039 |
Bicara Therapeutics Volatility Alert
Bicara Therapeutics Common shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Bicara Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Bicara Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Bicara Therapeutics Fundamentals Vs Peers
Comparing Bicara Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bicara Therapeutics' direct or indirect competition across all of the common fundamentals between Bicara Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bicara Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bicara Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Bicara Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bicara Therapeutics to competition |
| Fundamentals | Bicara Therapeutics | Peer Average |
| Return On Equity | -0.27 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Current Valuation | 531.89 M | 16.62 B |
| Shares Outstanding | 54.78 M | 571.82 M |
| Shares Owned By Insiders | 12.16 % | 10.09 % |
| Shares Owned By Institutions | 92.48 % | 39.21 % |
| Number Of Shares Shorted | 8.9 M | 4.71 M |
| Price To Book | 2.04 X | 9.51 X |
| EBITDA | (82.33 M) | 3.9 B |
| Net Income | (68 M) | 570.98 M |
| Total Debt | 738 K | 5.32 B |
| Book Value Per Share | 7.38 X | 1.93 K |
| Cash Flow From Operations | (74.75 M) | 971.22 M |
| Short Ratio | 20.17 X | 4.00 X |
| Earnings Per Share | 5.38 X | 3.12 X |
| Target Price | 30.8 | |
| Number Of Employees | 55 | 18.84 K |
| Market Capitalization | 820.09 M | 19.03 B |
| Total Asset | 569.2 M | 29.47 B |
| Retained Earnings | (221.02 M) | 9.33 B |
| Working Capital | 484.54 M | 1.48 B |
| Net Asset | 569.2 M |
Note: Acquisition by Meisner Lara of 90000 shares of Bicara Therapeutics at 16.76 subject to Rule 16b-3 [view details]
Bicara Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bicara . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 13.99 | |||
| Day Typical Price | 13.99 | |||
| Price Action Indicator | (0.41) | |||
| Period Momentum Indicator | (0.81) |
Bicara Therapeutics Target Price Consensus
Bicara target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Bicara Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Bicara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Bicara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Bicara Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBicara Therapeutics Target Price Projection
Bicara Therapeutics' current and average target prices are 13.99 and 30.80, respectively. The current price of Bicara Therapeutics is the price at which Bicara Therapeutics Common is currently trading. On the other hand, Bicara Therapeutics' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Bicara Therapeutics Market Quote on 12th of February 2026
Target Price
Analyst Consensus On Bicara Therapeutics Target Price
Bicara Therapeutics Analyst Ratings
Bicara Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Bicara Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Bicara Therapeutics' financials, market performance, and future outlook by experienced professionals. Bicara Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Bicara Therapeutics Buy or Sell Advice
When is the right time to buy or sell Bicara Therapeutics Common? Buying financial instruments such as Bicara Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bicara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Disruptive Technologies Thematic Idea Now
Disruptive Technologies
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.